Gambardella Valentina, Tarazona Noelia, Cejalvo Juan Miguel, Roselló Susana, Cervantes Andrés
a Department of Medical Oncology , Biomedical Research Institute INCLIVA, University of Valencia , Valencia , Spain.
Expert Opin Drug Metab Toxicol. 2016;12(4):449-56. doi: 10.1517/17425255.2016.1156084. Epub 2016 Mar 10.
Colorectal cancer is the third most common cancer worldwide. The prognosis of colorectal cancer patients still remains dismal and half of them will develop metastatic disease. Angiogenesis plays an essential role in colorectal tumorigenesis, and the VEGF pathway is one of the targets that has been validated up to now. The use of antiangiogenics along with chemotherapy has become an accepted standard for colorectal cancer.
This review discusses the efficacy and safety profile of ramucirumab, a fully human immunoglobulin G1 monoclonal antibody against the vascular endothelial growth factor receptor-2 (VEGFR-2), for the treatment of second-line metastatic colorectal cancer upon progression to first-line chemotherapy including anti-angiogenics.
Ramucirumab in combination with chemotherapy represents a valid option in second-line treatment of advanced colorectal cancer patients, who progressed on previous bevacizumab-based combinations. This agent demonstrates a similar benefit in terms of overall survival to other angiogenesis inhibitors (bevacizumab and ziv-aflibercept) used in this setting.
结直肠癌是全球第三大常见癌症。结直肠癌患者的预后仍然很差，其中一半会发展为转移性疾病。血管生成在结直肠癌的发生发展中起着至关重要的作用，血管内皮生长因子（VEGF）通路是目前已得到验证的靶点之一。抗血管生成药物与化疗联合使用已成为结直肠癌的公认标准。
本综述讨论了雷莫西尤单抗（一种针对血管内皮生长因子受体-2（VEGFR-2）的全人免疫球蛋白G1单克隆抗体）在一线化疗（包括抗血管生成药物）进展后用于治疗二线转移性结直肠癌的疗效和安全性。
雷莫西尤单抗与化疗联合使用是晚期结直肠癌患者二线治疗的有效选择，这些患者在先前基于贝伐单抗的联合治疗中病情进展。在总生存期方面，该药物与在这种情况下使用的其他血管生成抑制剂（贝伐单抗和阿柏西普）显示出相似的益处。
